Lexicon Pharmaceuticals (LXRX) Operating Margin (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 16 years of Operating Margin data on file, last reported at 4.72% in Q1 2026.

• On a quarterly basis, Operating Margin rose 203007.0% year-over-year to 4.72% in Q1 2026; TTM through Mar 2026 was 34.79%, a 53377.0% increase from a year earlier, with the FY2025 full-year figure at 98.21%, up 53600.0% from the prior year.
• Operating Margin for Q1 2026 stood at 4.72%, up from 269.07% in the prior quarter.
• Over the last five years, Operating Margin for LXRX reached as high as 12.94% in Q2 2025 and fell as low as 68591.43% in Q2 2022.
• Historically, Operating Margin has averaged 10321.92% across 5 years, with a median of 3360.9% in 2024.
• Across the five-year window, Operating Margin surged 5338868 bps in 2023 and slumped 14579 bps in 2025, its largest moves.
• Year by year, Operating Margin stood at 68591.43% in 2022, then jumped by 91 bps to 6101.44% in 2023, then soared by 98 bps to 123.28% in 2024, then slumped by 118 bps to 269.07% in 2025, then surged by 98 bps to 4.72% in 2026.
• Per Business Quant data, the three most recent Operating Margin figures were 4.72% in Q1 2026, 269.07% in Q4 2025, and 85.93% in Q3 2025.